Literature DB >> 30715557

A case of anaphylaxis to alemtuzumab.

Charles J S Nye1, Annette Wagner2, Onajite Kousin-Ezewu3, Joanne L Jones3, Alasdair J Coles3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30715557     DOI： 10.1007/s00415-019-09214-2

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  7 in total

1.  Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.

Authors:  Paul Moreton; Ben Kennedy; Guy Lucas; Michael Leach; Saad M B Rassam; Andrew Haynes; Jane Tighe; David Oscier; Christopher Fegan; Andy Rawstron; Peter Hillmen
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

2.  Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

Authors:  M G Wing; T Moreau; J Greenwood; R M Smith; G Hale; J Isaacs; H Waldmann; P J Lachmann; A Compston
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

3.  Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis (CARE-MS) Program.

Authors:  Christina Caon; Marie Namey; Cathy Meyer; Lori Mayer; Pedro Oyuela; David H Margolin; Marco Rizzo
Journal:  Int J MS Care       Date:  2015 Jul-Aug

4.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Authors:  Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Elizabeth Fisher; Vesna V Brinar; Gavin Giovannoni; Miroslav Stojanovic; Bella I Ertik; Stephen L Lake; David H Margolin; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

5.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Authors:  Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

6.  Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.

Authors:  A J Coles; M G Wing; P Molyneux; A Paolillo; C M Davie; G Hale; D Miller; H Waldmann; A Compston
Journal:  Ann Neurol       Date:  1999-09       Impact factor: 10.422

7.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245
  7 in total
  1 in total

1.  Successful Rapid Drug Desensitization with A Modified Protocol To Alemtuzumab in A Multiple Sclerosis Patient with Severe Immediate-Type Hypersensitivity Reaction.

Authors:  Ceyda Tunakan Dalgiç; Emine Nihal Mete Gökmen; Melih Özişik; Meltem Alkaya Baklan; Nur Yüceyar
Journal:  Noro Psikiyatr Ars       Date:  2022-08-16       Impact factor: 1.066
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.